H. Lundbeck A/S
H. Lundbeck A/S is a Danish biopharmaceutical company focused on medicines for brain disorders. Its portfolio centers on neurology and psychiatry, including treatments for migraine, epilepsy, depression, schizophrenia, and other central nervous system conditions, marketed through Lundbeck’s own commercial network and partners across global markets.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueApproved prescription drugs sold through Lundbeck’s own and partnered channels.
Products and late-stage programs addressing chronic and episodic migraine.
Therapies and pipeline assets for developmental epilepsies and seizures.
Treatments for depression, schizophrenia, and related brain disorders.
External commercialization arrangements and smaller legacy or non-core revenue.
Customers
Lundbeck sells mainly to healthcare systems, hospitals, physicians, and pharmacies that prescribe or dispense central nervous system medicines. It also works with commercial partners in selected markets, where local pharmaceutical companies help distribute and promote Lundbeck-branded products. Demand is driven by diagnosis rates, physician adoption, reimbursement access, and the clinical differentiation of branded CNS therapies.
Prescribe migraine and epilepsy medicines, including branded specialty therapies and pipeline products.
Use Lundbeck’s psychiatry portfolio for depression, schizophrenia, and related disorders.
Buy or administer treatments for complex brain disorders and severe patient populations.
Dispense prescribed medicines to patients under reimbursed retail or hospital channels.
Market Lundbeck products in partner territories under licensing or distribution agreements.
Strategy
Lundbeck’s strategy is centered on brain disorders, with a focus on growing branded commercial franchises and advancing a late-stage pipeline. It is combining internal R&D, selective partnering, and business development to build a larger base of specialty neurology and psychiatry assets over time.
These medicines provide the commercial base that funds research and expansion.
Pipeline success is needed to replenish the product portfolio and sustain growth.
Partnerships increase geographic reach without requiring a full local sales buildout.
Deals can add assets and scale in rare disease and specialty CNS areas.
Geography
Lundbeck is headquartered in Denmark and operates across more than 20 countries, with products sold in more than 80 countries. The business is international in reach, with commercial activity concentrated in major developed pharmaceutical markets and a growing partner-market footprint across additional regions.
Risks
Lundbeck depends on clinical and regulatory success in a concentrated set of CNS programs, so setbacks in trials or approvals can affect future product depth. It also faces typical pharmaceutical risks such as payer pressure, patent and lifecycle exposure, launch execution risk, and foreign-exchange sensitivity across a global commercial footprint.
- Clinical trial failureImpact: HighLikelihood: Medium
Late-stage CNS programs may not meet efficacy or safety endpoints, reducing future revenue potential.
Exposure - Regulatory approval delaysImpact: HighLikelihood: Medium
Drug launches depend on approvals in each market, and timing can shift by country and indication.
Exposure - Product concentrationImpact: HighLikelihood: Medium
A large share of revenue comes from strategic brands, so brand erosion would affect results disproportionately.
Exposure: Strategic brands and migraine franchise
- Reimbursement and pricing pressureImpact: MediumLikelihood: High
Neurology drugs rely on payer access and formulary placement, which can compress uptake or net prices.
Exposure: Developed pharmaceutical markets
- Foreign exchange volatilityImpact: MediumLikelihood: High
Global sales and costs are denominated in multiple currencies, creating translation and transaction exposure.
Exposure
Accounting
Judgemental itemsAcquired products and know-how are amortized over useful lives, affecting operating profit after acquisitions.
Impact: Higher amortization after acquisitions can reduce reported earnings versus cash performance.
Milestone-based acquisition payments are measured using discounted cash flow and probability assumptions.
Impact: Changes in clinical prospects can create fair-value swings in the income statement.
Management excludes integration, restructuring, impairment, and similar items from the non-GAAP measure.
Impact: Investors should compare adjusted and statutory results to assess underlying performance.
Development assets and acquired know-how can materially affect reported R&D expense and comparability.
Impact: Timing of pipeline progress and asset lives changes earnings recognition.
Similar listed companies
Publicly listed companies with a comparable business focus.
LB Pharmaceuticals Inc
LBRX · Pharmaceutical Preparations
Supernus Pharmaceuticals, Inc
SUPN · Pharmaceutical Preparations
Supernus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases.
BioArctic
BIOA-B · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Xenon Pharmaceuticals Inc.
XENE · Pharmaceutical Preparations
Alkermes plc.
ALKS · Pharmaceutical Preparations
Alkermes plc is a biopharmaceutical company focused on neuroscience, with commercial medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy.
Jazz Pharmaceuticals plc
JAZZ · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology.
Last updated: 24/10/2026